A detailed history of Kynam Capital Management, LP transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Kynam Capital Management, LP holds 1,371,511 shares of TVTX stock, worth $24.5 Million. This represents 1.57% of its overall portfolio holdings.

Number of Shares
1,371,511
Previous 2,021,659 32.16%
Holding current value
$24.5 Million
Previous $16.6 Million 15.46%
% of portfolio
1.57%
Previous 1.29%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$7.89 - $15.21 $5.13 Million - $9.89 Million
-650,148 Reduced 32.16%
1,371,511 $19.2 Million
Q2 2024

Aug 14, 2024

BUY
$5.26 - $8.28 $113,926 - $179,336
21,659 Added 1.08%
2,021,659 $16.6 Million
Q4 2023

Feb 14, 2024

BUY
$5.44 - $9.5 $5.67 Million - $9.9 Million
1,042,498 Added 108.88%
2,000,000 $18 Million
Q3 2023

Nov 14, 2023

SELL
$7.64 - $17.25 $3.8 Million - $8.58 Million
-497,228 Reduced 34.18%
957,502 $8.56 Million
Q2 2023

Aug 14, 2023

SELL
$15.3 - $22.61 $1.67 Million - $2.46 Million
-108,865 Reduced 6.96%
1,454,730 $22.3 Million
Q1 2023

May 15, 2023

BUY
$17.82 - $22.89 $20.4 Million - $26.2 Million
1,145,496 Added 273.98%
1,563,595 $35.2 Million
Q4 2022

Feb 14, 2023

BUY
$18.47 - $26.14 $25,303 - $35,811
1,370 Added 0.33%
418,099 $8.79 Million
Q3 2022

Nov 14, 2022

SELL
$22.91 - $28.63 $18.8 Million - $23.4 Million
-818,422 Reduced 66.26%
416,729 $10.3 Million
Q2 2022

Aug 15, 2022

BUY
$20.94 - $30.01 $7.63 Million - $10.9 Million
364,233 Added 41.82%
1,235,151 $29.9 Million
Q1 2022

May 13, 2022

BUY
$23.61 - $30.6 $16.3 Million - $21.1 Million
688,815 Added 378.26%
870,918 $22.4 Million
Q4 2021

Feb 14, 2022

BUY
$24.34 - $31.17 $4.43 Million - $5.68 Million
182,103 New
182,103 $5.65 Million

Others Institutions Holding TVTX

About Travere Therapeutics, Inc.


  • Ticker TVTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 64,173,600
  • Market Cap $1.15B
  • Description
  • Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...
More about TVTX
Track This Portfolio

Track Kynam Capital Management, LP Portfolio

Follow Kynam Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kynam Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Kynam Capital Management, LP with notifications on news.